Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00090623 · ClinicalTrials.gov registry record · Phase 3
A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)
A Phase 3 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 3
- Development phase
- 180
- Enrollment target
NCT00090623 is a Phase 3 study that has completed, run by Genentech. The registered enrollment target is 180 participants.
The verdict
NCT00090623, a Phase 3 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 180 participants
- Enrollment target
Study Summary
This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Interventions
- DRUG rhuFab V2 (ranibizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2004-08 |
| Est. Completion | 2007-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00090623
The ClinicalTrials.gov registry entry for NCT00090623 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rhuFab V2 (ranibizumab) is the first listed.
NCT00090623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00090623 about?
NCT00090623 is a clinical study titled "A Study of rhuFab V2 (Ranibizumab) in Subjects With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD)". This is a phase III, multicenter, randomized, double masked, sham injection-controlled study of the efficacy and safety of intravitreally administered ranibizumab in subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
What is the current status of trial NCT00090623?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 180 participants. The study started on 2004-08. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00090623?
The interventions under investigation include: rhuFab V2 (ranibizumab) (DRUG).
Who is sponsoring clinical trial NCT00090623?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.